Avadel Pharmaceuticals sees Q3 revenue $71M-$75M, consensus $70.61M

Providing guidance for the quarter ending September 30, 2025 of $71 – $75 million in net product revenue and cash operating expenses of $50 – $55 million. Given the positive return from prior investments, operating expense guidance includes additional investments in LUMRYZ for further sales force expansion and additional patient and physician marketing programs.